Table 1.
Drug delivery mechanism | Antiretroviral | Particle composition | Manufacture method | Finding | Ref. |
---|---|---|---|---|---|
BBB disruption | Saquinavir | PBCA and MMA-SPM | Emulsion polymerization and free-radical polymerization | Application of AM waves greatly increases permeability of BMVECs to HIV-drug NPs | [99] |
Nelfinavir, zidovudine and lamivudine | Pluronic® 85 | Nanomaterial used as is | Pluronic 85 greatly increases the permeability of the BBB in vitro/in vivo to ART | [33,104] | |
Adsorptive endocytosis by BMVEC | Saqunavir | Core: Compritol 888 ATO, cacao butter Shell: stearylamine, dioctadecyldimethyl ammonium bromide Stabilizer: polysorbate 80 | Emulsion polymerization and free-radical polymerization | Decreased initial burst of drug release and extended overall time of drug release | [117] |
Zidovudine | PBCA and MMA-SPM | Emulsion polymerization and free-radical polymerization | PBCA as a carrier; alcohol increases permeability of BMVECs to NPs | [114] | |
Cell-mediated delivery | Phosphonylmethoxypropyl-adenine and indinavir | Egg phosphatidylcholine and cholesterol | Sonication | NPs stable at physiologic pH and disassociate at low pH | [135] |
Indinavir | Drug nanocrystals and lipoid E80 | High-pressure homogenization | Avid uptake and long-term release by MDMs | [31,32] | |
Indinavir | Drug nanocrystals and mPEG-DSPE | High-pressure homogenization | Adoptive transfer of NP-loaded MDMs can significantly improve outcome in a mouse model of HIVE | [34] |
AM: Amplitude modulation; ART: Antiretroviral therapy; BBB: Blood-brain barrier; BMVEC: Brain microvessel endothelial cell; HIVE: HIV-1 encephalitis; MDM: Monocyte-derived macrophage; MMA-SPM: Methylmethacrylate-sulfopropylmethacrylate; mPEG-DPSE: Methyl polyethylene glycol-disteroyl phosphatidylethanolamine; NP: Nanoparticle; PBCA: Polybutylcyanoacrylate.